States seek to expand lawsuit against generic drug-makers

October 31, 2017

Connecticut's attorney general and 45 of his colleagues are seeking to expand a federal antitrust lawsuit against generic drug-makers to include more manufacturers and medications, as well as senior executives at two companies.

Led by Connecticut, the states sought a 's permission Tuesday to widen their complaint, which alleges a number of illegal agreements among 18 manufacturers to fix prices and divvy up the market for specific .

The original lawsuit filed last year claimed six drug-makers artificially inflated and manipulated prices for two drugs. At the time, Connecticut Attorney General George Jepsen said "it was just the tip of the iceberg."

Jepsen says the alleged collusion is "so pervasive that it essentially eliminated competition from the market" for 15 generic drugs.

Explore further: Connecticut leads 20-state lawsuit over drug pricing

Related Stories

Connecticut leads 20-state lawsuit over drug pricing

December 15, 2016
Six generic drug-makers artificially inflated and manipulated prices to reduce competition for an antibiotic and oral diabetes medication, 20 state attorneys general, led by Connecticut, said in a federal lawsuit filed Thursday.

Generic drugmakers want antitrust lawsuit dismissed

May 3, 2017
Six generic drugmakers are asking a federal judge in Connecticut to dismiss a 40-state lawsuit accusing them of artificially inflating and manipulating prices to reduce competition for antibiotic and oral diabetes medication.

FDA takes steps to boost generic competition, limit prices

June 27, 2017
The Food and Drug Administration is taking steps to boost the number of generic prescription drugs in an effort to make medicines more affordable and to prevent price gouging.

As competition goes down, generic drug prices rise, study finds

July 3, 2017
If the cost of your generic prescription drug has risen, it may be due to a lack of competition among drug manufacturers, according to a University of Florida College of Pharmacy study.

High court ruling speeds up generic biotech drug approval

June 12, 2017
The Supreme Court is speeding up the time for generic biotech drugs to become available to the public. The court's unanimous ruling Monday means a loss of billions in sales to makers of original versions.

Recommended for you

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.